The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol

Vaccine

Volumn 17, Issue 6, 1999, Pages 512-529

  Lavelle, E C ^a   Yeh, M K ^a   Coombes, A G A ^a   Davis, S S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Controlled release; IgG subtypes; Immune response; Microparticles; Poly(L lactide); Poly(lactide co glycolide); Protein degradation; Stability; Vaccine

Indexed keywords

ADJUVANT; ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MACROGOL; OVALBUMIN; POLYGLACTIN; POLYMER; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; DENSITOMETRY; DRUG FORMULATION; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZE DRYING; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIGENS; BIODEGRADATION, ENVIRONMENTAL; FEMALE; HYDROGEN-ION CONCENTRATION; IMMUNIZATION; IMMUNOGLOBULIN G; LACTIC ACID; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; OVALBUMIN; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS;

EID: 0033547970     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00229-1     Document Type: Article

References (42)

1. Husband A.J., Bao S., McClure S.J., Emery D.L., Ramsay A.J. Antigen delivery strategies for mucosal vaccines. Int J Parasitol. 26:1996;825-834.
2. Powell M.F. Drug delivery issues in vaccine development. Pharm Res. 13:1996;1777-1785.
3. Warren H.S., Chedid L.A. Future prospects for vaccine adjuvants. CRC Crit Rev Immunol. 8:1988;83-101.
4. Men Y., Thomasin C., Merkle B., Gander G., Corradin A. A single administration of tetanus toxoid in biodegradable microspheres elicits T-cell and antibody responses similar or superior to those obtained with aluminium hydroxide. Vaccine. 12:1995;683-689.
5. Singh M., Li X.-M., Wang H., McGee J.P., Zamb T., Koff W., Wang C.Y., O'Hagan D.T. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun. 65:1997;1716-1721.
6. Singh M., Singh O., Singh A., Talwar G.P. Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres. Int J Pharm. 85:1992;R5-R8.
7. Vordermeier M., Coombes A.G.A., Jenkins P., McGee J.P., O'Hagan D.T., Davis S.S., Singh M. Synthetic delivery systems for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable microparticles. Vaccine. 13:1995;1576-1582.
8. Lavelle E.C., Sharif S., Thomas N.W., Holland J., Davis S.S. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev. 18:1995;5-22.
9. Eldridge J.H., Staas J.K., Meulbroek J.A., McGhee J.R., Tice T.R., Gilley R.M. Biodegradable microspheres as a vaccine delivery system. Mol Immunol. 28:1991;287-294.
10. Raghuvanshi R.S., Singh M., Talwar G.P. Biodegradable delivery system for single step immunisation with tetanus toxoid. Int J Pharm. 93:1993;R1-R5.
11. O'Hagan D.T., Rahman D., McGhee J.P., Jeffery H., Davies M.C., Williams P., Davis S.S. Biodegradable microparticles as controlled release antigen delivery systems. Immunology. 73:1991;239-242.
12. Tabata Y., Ikada Y. Protein precoating of polylactide microspheres containing a lipophilic immunopotentiator for enhancement of macrophage phagocytosis and activation. Pharm Res. 6:1989;296-301.
13. Scheicher C., Mehlig M., Dienes H.-P., Reske K. Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1α and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol. 25:1995;1566-1572.
14. Coombes A.G.A., Lavelle E.C., Jenkins P.G., Davis S.S. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine. 14:1996;1429-1438.
15. O'Hagan D.T., Jeffery H., Davis S.S. Long term antibody responses in mice following subcutaneous immunisation with ovalbumin entrapped in biodegradable microparticles. Vaccine. 11:1993;965-969.
16. Gombotz W.R., Pettit D.K. Biodegradable polymers for protein and peptide drug delivery. Bioconjugate Chem. 6:1995;332-351.
17. Park T.G., Lu W., Crotts G. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly(DL-lactic acid-co-glycolic acid) microspheres. J Control Rel. 33:1995;211-222.
18. Takahata H., Lavelle E.C., Coombes A.G.A., Davis S.S. The distribution of protein associated with poly(DL-lactide-co-glycolide) microparticles and its degradation in simulated body fluids. J Control Rel. 50:1998;237-248.
19. Alonso M.J., Cohen S., Park T.G., Gupta R.K., Siber G.R., Langer R. Determination of release rate of tetanus vaccine from polyester microspheres. Pharm Res. 10:1993;945-953.
20. Yeh M.K., Jenkins P.G., Davis S.S., Coombes A.G.A. Improving the delivery capacity of microparticle systems using blends of poly(DL lactide co-glycolide) and poly(ethylene glycol). J Control Rel. 37:1995;1-9.
21. Yeh M.K., Coombes A.G.A., Jenkins P.G., Davis S.S. A novel emulsification-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery. J Control Rel. 33:1995;437-445.
22. Laemmli U.K. Cleavage of the structural protein during the assembly of the head of bacteriophage T4. Nature. 227:1970;600-605.
23. Powell M.F., Cleland J.L., Shire S.J. The development of stable protein formulations: A close look at protein aggregation, deamidation and oxidation. Crit Rev Ther Drug Carrier Sys. 10:1993;307-377.
24. O'Hagan D.T., McGee J.P., Boyle R., Gumaer D., Li X.-M., Potts B., Wang C.Y., Koff W.C. The preparation, characterization and pre-clinical evaluation of an orally administered HIV-1 vaccine, consisting of a branched peptide immunogen entrapped in controlled release microparticles. J Control Rel. 36:1995;75-84.
25. Jones D.H., McBride B.W., Farrar G.H. Poly(lactide-co-glycolide) microencapsulation of vaccine antigens. J Biotechnol. 44:1996;29-36.
26. Xing D.K.-L., Crane D.T., Bolgiano B., Corbel M.J., Jones C., Sesardic D. Physiochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. Vaccine. 14:1996;1205-1213.
27. Li S., Garreau H., Vert M. Structure property relationships in the case of the degradation of massive poly(α-hydroxy acids) in aqueous media. Part 1. Poly(DL lactic acid). J Mater Sci Mater Med. 1:1990;123-130.
28. Park T.G. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials. 16:1995;1123-1130.
29. Pitt C.G., Chasalow F.I., Hibionda Y.M., Klimas D.M., Schindler A. Aliphatic polyesters. I. The degradation of poly(ε-caprolactone) in vivo. J Appl Pol Sci. 26:1981;3779-3787.
30. Sharif S., O'Hagan D.T. A comparison of alternative methods for the determination of the levels of proteins entrapped in poly(lactide co-glycolide) microparticles. Int J Pharm. 115:1995;259-263.
31. Hora M.S., Rana R.K., Nunberg J.H., Tice T.R., Gilley R.M., Hudson M.E. Release of human serum albumin from poly(lactide co-glycolide) microspheres. Pharm Res. 7:1990;1190-1194.
32. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery systems for protein based on poly(lactic/glycolic acid) microspheres. Pharm Res. 8:1991;713-720.
33. Gupta R.K., Siber G.R. Adjuvants for human vaccines: current status, problems and future prospects. Vaccine. 13:1995;1276-1283.
34. Cohen S., Bernstein C., Hewes C., Chow M., Langer R. The pharmacokinetics of and humoral response to antigen delivered by microencapsulated liposomes. Proc Natl Acad Sci USA. 88:1991;10440-10444.
35. Matlaga B., Yasenchak L., Salthouse T. Tissue response to implanted polymers. The significance of sample shape. J Biomed Mater Res. 10:1976;391-397.
36. Coombes A.G.A., Major D., Wood J.M., Hockley D.J., Minor P.D., Davis S.S. Resorbable lamellar particles of lactide polymers as adjuvants for influenza virus vaccines. Biomaterials. 19:1998;81-1073.
37. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., Okahashi N., Yamamoto M., Kiyono H., Bluthmann H., Fujihashi K., McGhee J.R. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol. 155:1995;4621-4629.
38. Mossmann T.R., Coffman R.L. Th1 cell and Th2 cell: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol. 7:1989;145-173.
39. Snapper C.M., Paul W.E. Interferon-γ and B-cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 236:1987;944-947.
40. + Th1 cells. Vaccine. 13:1995;1741-1749.
41. Rafferty D.E., Elfaki M.G., Montgomery P.C. Preparation and characterization of a biodegradable microparticle antigen/cytokine delivery system. Vaccine. 14:1996;532-538.
42. Yeh M.K., Davis S.S., Coombes A.G.A. Improving protein delivery from microparticles using blends of poly(DL lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers. Pharm Res. 13:1996;693-698.